▶Crizotinibis predicted to increase the exposure to
antiarrhythmics(propafenone). Monitor and adjust dose.
oStudy
▶Antiepileptics(carbamazepine, fosphenytoin, phenobarbital,
phenytoin, primidone)are predicted to markedly decrease the
exposure tocrizotinib. Avoid.rStudy
▶Antifungals, azoles(itraconazole, ketoconazole, voriconazole)are
predicted to moderately increase the exposure tocrizotinib.
Avoid.oStudy→Also seeTABLE 9p. 849
▶Crizotinibis predicted to increase the exposure to
antihistamines, non-sedating(mizolastine).rTheoretical
▶Crizotinibis predicted to increase the exposure to
antihistamines, non-sedating(rupatadine). Avoid.oStudy
▶Crizotinibis predicted to increase the concentration of
antimalarials(piperaquine).rTheoretical
▶Crizotinibis predicted to increase the exposure toaxitinib.
oTheoretical→Also seeTABLE 15p. 850
▶Crizotinibis predicted to increase the exposure tobedaquiline.
Avoid prolonged use.nTheoretical→Also seeTABLE 9p. 849
▶Bosentanis predicted to decrease the exposure tocrizotinib.
Avoid.rTheoretical
▶Crizotinibis predicted to increase the exposure tobosutinib.
Avoid or adjust dose.rTheoretical→Also seeTABLE 15
p. 850→Also seeTABLE 9p. 849
▶Crizotinibis predicted to increase the exposure tobuspirone.
Use with caution and adjust dose.oStudy
▶Crizotinibis predicted to increase the exposure to
cabozantinib.oTheoretical→Also seeTABLE 15p. 850→
Also seeTABLE 9p. 849
▶Crizotinibis predicted to increase the exposure tocalcium
channel blockers(amlodipine, felodipine, lacidipine,
lercanidipine, nicardipine, nifedipine, nimodipine). Monitor and
adjust dose.oStudy
▶Crizotinibis predicted to increase the exposure toceritinib.
oTheoretical→Also seeTABLE 15p. 850→Also seeTABLE 9
p. 849
▶Crizotinibincreases the concentration ofciclosporin.r
Study
▶Cobicistatis predicted to moderately increase the exposure to
crizotinib. Avoid.oStudy
▶Crizotinibis predicted to increase the exposure tocobimetinib.
rTheoretical
▶Crizotinibis predicted to increase the exposure tocolchicine.
Adjustcolchicinedose with moderate inhibitors of CYP3A4.
rStudy
▶Crizotinibis predicted to increase the exposure to
corticosteroids(methylprednisolone). Monitor and adjust dose.
oStudy
▶Crizotinibis predicted to increase the risk of bleeding events
when given withcoumarins.rTheoretical
▶Crizotinibis predicted to slightly increase the exposure to
darifenacin.oStudy
▶Crizotinibis predicted to increase the exposure todasatinib.
rStudy→Also seeTABLE 15p. 850→Also seeTABLE 9p. 849
▶Crizotinibincreases the risk of QT-prolongation when given
withdomperidone. Avoid.rStudy
▶Crizotinibis predicted to increase the exposure todopamine
receptor agonists(bromocriptine).rTheoretical
▶Crizotinibis predicted to increase the concentration of
dopamine receptor agonists(cabergoline).oAnecdotal
▶Crizotinibis predicted to moderately increase the exposure to
dutasteride.nStudy
▶Efavirenzis predicted to decrease the exposure tocrizotinib.
Avoid.rTheoretical→Also seeTABLE 9p. 849
▶Crizotinibis predicted to increase the exposure toeliglustat.
Avoid or adjust dose—consult product literature.rStudy
▶Enzalutamideis predicted to markedly decrease the exposure
tocrizotinib. Avoid.rStudy
▶Crizotinibis predicted to increase the risk of ergotism when
given withergometrine.rTheoretical
▶Crizotinibis predicted to increase the risk of ergotism when
given withergotamine.rTheoretical
▶Crizotinibis predicted to increase the exposure toerlotinib.
oTheoretical
▶Crizotinibis predicted to increase the concentration of
everolimus. Avoid or adjust dose.oStudy→Also see
TABLE 15p. 850
▶Crizotinibis predicted to increase the exposure to
fesoterodine. Adjustfesoterodinedose with moderate
inhibitors of CYP3A4 in hepatic and renal impairment.n
Study
▶Crizotinibis predicted to increase the exposure togefitinib.
oTheoretical→Also seeTABLE 15p. 850
▶Crizotinibpotentially decreases the exposure toglecaprevir.
Avoid.rTheoretical
▶Grapefruit juiceis predicted to increase the exposure to
crizotinib. Avoid.oTheoretical
▶Crizotinibis predicted to increase the concentration of
guanfacine. Adjustguanfacinedose,p. 231.oTheoretical
▶HIV-protease inhibitorsare predicted to moderately increase
the exposure tocrizotinib. Avoid.oStudy→Also see
TABLE 9p. 849
▶Crizotinibis predicted to increase the exposure toibrutinib.
Adjustibrutinibdose with moderate inhibitors of CYP3A4.
rStudy→Also seeTABLE 15p. 850
▶Idelalisibis predicted to moderately increase the exposure to
crizotinib. Avoid.oStudy→Also seeTABLE 15p. 850
▶Crizotinibis predicted to increase the exposure toivabradine.
Adjustivabradinedose.rTheoretical→Also seeTABLE 6
p. 848
▶Crizotinibis predicted to increase the exposure toivacaftor.
Adjustivacaftordose with moderate inhibitors of CYP3A4,
p. 186.rStudy
▶Crizotinibis predicted to increase the exposure tolapatinib.
oStudy→Also seeTABLE 9p. 849
▶Crizotinibis predicted to increase the exposure tolomitapide.
Avoid.oTheoretical
▶Crizotinibis predicted to increase the exposure tolurasidone.
oStudy
▶Macrolides(clarithromycin)are predicted to moderately
increase the exposure tocrizotinib. Avoid.oStudy→
Also seeTABLE 9p. 849
▶Crizotinibis predicted to increase the exposure tomidazolam.
Monitor side effects and adjust dose.rStudy
▶Crizotinibis predicted to increase the exposure tomidostaurin.
oTheoretical
▶Mitotaneis predicted to markedly decrease the exposure to
crizotinib. Avoid.rStudy→Also seeTABLE 15p. 850
▶Crizotinibis predicted to increase the exposure tonaloxegol.
Adjustnaloxegoldose and monitor side effects.oStudy
▶Nevirapineis predicted to decrease the exposure tocrizotinib.
Avoid.rTheoretical
▶Crizotinibis predicted to increase the exposure toolaparib.
Avoid moderate inhibitors of CYP3A4 or adjustolaparibdose.
oTheoretical→Also seeTABLE 15p. 850
▶Crizotinibis predicted to increase the exposure toopioids
(alfentanil, buprenorphine, fentanyl, oxycodone). Monitor and
adjust dose.oStudy→Also seeTABLE 6p. 848
▶Crizotinibis predicted to increase the exposure toopioids
(methadone, sufentanil).oTheoretical→Also seeTABLE 6
p. 848→Also seeTABLE 9p. 849
▶Crizotinibis predicted to increase the exposure tooxybutynin.
nTheoretical
▶Crizotinibis predicted to increase the exposure topazopanib.
oTheoretical→Also seeTABLE 15p. 850→Also seeTABLE 9
p. 849
▶Crizotinibis predicted to increase the risk of bleeding events
when given withphenindione.rTheoretical
▶Crizotinibis predicted to increase the exposure to
phosphodiesterase type-5 inhibitors(avanafil). Adjustavanafil
dose.oTheoretical
▶Crizotinibis predicted to increase the exposure to
phosphodiesterase type-5 inhibitors(sildenafil). Monitor or
adjustsildenafildose with moderate inhibitors of CYP3A4,
p. 120.oStudy→Also seeTABLE 9p. 849
▶Crizotinibis predicted to increase the exposure to
phosphodiesterase type-5 inhibitors(tadalafil).rTheoreticalBNFC 2018 – 2019 Crizotinib—Crizotinib 905
Interactions|Appendix 1A1